Showing 2 posts of 2 posts found.


AstraZeneca’s roxadustat boosts haemoglobin levels in two Phase 3 trials

November 8, 2019
Medical Communications, Research and Development AstraZeneca, pharma, roxadustat

AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) …

Astellas’ chronic kidney drug shows superiority at Phase 3

September 20, 2018
Research and Development Astellas, chronic kidney disease, pharma, roxadustat

Astellas has revealed new Phase 3 data for roxadustat in the treatment of chronic kidney disease (CKD) in patients with …

Latest content